Vonoprazan Fumarate

Overview

Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB) , with antisecretory activity. Vonoprazan Fumarate inhibits H + ,K + -ATPase activity in porcine gastric microsomes with an IC 50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease.

Application

Products | Products > Disease Areas > Gastroesophageal Reflux Disease | Products > Disease Areas > Gastric Ulcer | Products > Disease Areas > Infection | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Gastric Disease | Products > Disease Areas > Bacterial Infection | Products > Disease Areas > Peptic Ulcer Disease | Products > Disease Areas > Helicobacter Pylori Infection | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Signaling Pathways > Proton Pump

Product Information

• Catalog No.: HY-15295
• CAS No.: 881681-01-2
• Molecular Formula: C21H20FN3O6S
• Molecular Weight: 461.46
• Purity: 101.1%
• Storage: 4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
• Solubility: ≥ 2.5 mg/mL (5.42 mM); Clear solution
• Availability: In-stock

Source

Original product source